Company and share information

 

Company Information

Company name: CombiGene AB (publ)
Purpose: The purpose of the company is to develop new treatment for neurological diseases with better precision, increased efficacy and fewer side effects.
CEO: Jan Nilsson
Chairman of the Board of Directors: Bert Junno
No. of employees: 4
Corporate registration number: 556403-3818
Registered address: Medicon Village, 223 81 Lund
Visiting address: Medicon Village, Scheelevägen 2, Lund
Homepage: www.combigene.com
E-mail: info@combigene.com
Phone: + 46 704 66 31 63

The share

The share capital of the Company shall amount to no less than SEK 1 500 000 and no more than SEK 6 000 000 divided into no less than 15 000 000 shares and no more than 60 000 000 shares. CombiGene has one class of share. Each share carries equal rights to CombiGene’s assets and profits and is entitled to one vote at the Annual General Meeting. The quota value is SEK 0,1. The CombiGene share register is maintained electronically by Euroclear.
The share trades under the name Combigene, the ticker is COMBI, and the ISIN-Code is SE0006288189.

Link to Development of share capital >>

Please be advised that the English IR pages of the website is a translation of the Swedish version. It does not constitute an offer to purchase securities, and it is not directed at persons who reside in jurisdictions outside Sweden where a purchase of securities require measures other than those required under Swedish law.

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook